An interventional study of Furosemide 40 mg and Lasix® 40 mg Tablet in Drug Use, sponsored by PT. Kimia Farma (Persero) Tbk. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-02.
Sponsored by PT. Kimia Farma (Persero) Tbk (part of PT Bio Farma) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this research was to investigate whether Furosemide 40 mg tablet manufactured by PT. Kimia Farma Tbk was bioequivalent to its reference drug and Lasix® 40 mg Tablet manufactured by PT. Aventis Pharma, Indonesia.
Twenty four healty volunteers were given a single dose of Furosemide 40 mg Tablet or Lasix® 40 mg Tablet with 240 mL of water beneath fasting condition. Then the blood samples for Furosemide were drawn and analyzed using UPLC. All subjects sample plasma were analyzed for pharmacokinetic evaluation
PT. Kimia Farma (Persero) Tbk is the lead sponsor of 4 studies on the registry; none are open to participants now.
First submitted after PT. Kimia Farma (Persero) Tbk became part of PT Bio Farma.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
volunteers received Furosemide 40 mg tablet with 240 mL of water
Drug: Furosemide 40 mg
volunteers received Lasix® 40 mg tablet with 240 mL of water
Drug: Lasix® 40 mg Tablet
Administered with 240 mL of water
Administered with 240 mL of water
Also known as: Furosemide 40 mg
Geometric Mean Ratio of Maximum Concentration
The ratio between test drug and reference drug
Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Geometric Mean Ratio of Area Under Curve
The ratio between test drug and reference drug
Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Pharmacokinetics Parameter
Maximum plasma concentration
Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
Pharmacokinetics Parameter
Area Under Curve from 0 to 24 hours
Time frame: before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours after drug administration
24 healthy volunteers were recruited from one research
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
| Milestone | Test Drug First, Then Reference Drug | Reference Drug First, Then Test Drug |
|---|---|---|
| Started | 12 | 12 |
| Completed | 12 | 12 |
| Not completed | 0 | 0 |
The ratio between test drug and reference drug
| percentage | Furosemide 40 mg Tablet |
|---|---|
| Geometric Mean Ratio of Maximum Concentration | 104.51 (90.81 to 120.29) |
The ratio between test drug and reference drug
| percentage | Furosemide 40 mg Tablet |
|---|---|
| Geometric Mean Ratio of Area Under Curve | 101.79 (95.08 to 108.98) |
Maximum plasma concentration
| ng/mL | Furosemide 40 mg Tablet | Lasix® 40 mg Tablet |
|---|---|---|
| Pharmacokinetics Parameter | 1893.09 ± 479.62 | 1907.32 ± 707.72 |
Area Under Curve from 0 to 24 hours
| ng*h/mL | Furosemide 40 mg Tablet | Lasix® 40 mg Tablet |
|---|---|---|
| Pharmacokinetics Parameter | 4938.79 ± 1110.92 | 4921.94 ± 1279.14 |
Collected over before dosing (0 h) and at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 and 24 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Furosemide 40 mg Tablet | 0/24 (0%) | 0/24 (0%) | 5/24 (20.8%) |
| Lasix® 40 mg Tablet | 0/24 (0%) | 0/24 (0%) | 5/24 (20.8%) |
| Event | Furosemide 40 mg Tablet | Lasix® 40 mg Tablet |
|---|---|---|
| HeadacheNervous system disorders | 3/24 | 2/24 |
| PolyuriaGastrointestinal disorders | 1/24 | 2/24 |
| Frequent urinationGastrointestinal disorders | 2/24 | 1/24 |
24 healthy volunteers
| Age, Categorical(Participants) | Total Number of Participants |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Total Number of Participants |
|---|---|
| Female | 8 |
| Male | 16 |
| Race and Ethnicity Not Collected(Participants) | Total Number of Participants |
|---|
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2019 to primary completion in Jan 2020, 1 month.
Results were first posted in Nov 2023, 3 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Furosemide
PT. Kimia Farma (Persero) Tbk →